Product Overview

Oxra 5 mg is a prescription oral antidiabetic medication that contains the active ingredient dapagliflozin. It belongs to the class of sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors and is manufactured by Sun Pharmaceutical Industries Ltd. Each strip contains 14 tablets, and the product is also available in pack sizes of 28, 56, and 84 tablets for patient convenience. Oxra is indicated for the treatment of type 2 diabetes mellitus, and it is often used alongside diet and exercise to improve glycemic control. The medication is supplied in a blister pack that holds 14 tablets, ensuring dose integrity and ease of use.

What is Oxra 5 mg (Dapagliflozin)

Oxra 5 mg works by selectively inhibiting the SGLT2 protein in the proximal renal tubules of the kidneys. This inhibition prevents the reabsorption of glucose, leading to increased urinary glucose excretion. By lowering blood glucose levels without stimulating insulin secretion, Oxra offers a mechanism of action that is complementary to traditional oral hypoglycemics and insulin therapy. The drug is chemically identified as (R)-2‑amino‑2‑deoxy‑α‑D‑glucopyranoside, and its pharmacological profile has been extensively reviewed in peer‑reviewed literature and regulatory dossiers.

Uses and Benefits

The primary use of Oxra 5 mg is to improve glycemic control in adults with type 2 diabetes who have not achieved adequate HbA1c reduction with diet and exercise alone. Clinical studies have demonstrated that treatment with dapagliflozin can reduce HbA1c by approximately 0.5% to 0.8% on average, while also providing modest weight loss and blood pressure reductions. Additional benefits observed in cardiovascular outcome trials include a decreased risk of hospitalization for heart failure and a lower incidence of renal events in patients with chronic kidney disease. These attributes make Oxra a valuable option for patients with type 2 diabetes who also have cardiovascular or renal risk factors.

How It Works

After oral administration, dapagliflozin is rapidly absorbed and undergoes minimal metabolism, reaching peak plasma concentrations within one to two hours. The drug is then filtered by the kidneys and excreted both unchanged and as metabolites. Its mechanism hinges on blocking the SGLT2 transporter, which normally reabsorbs approximately 90% of filtered glucose back into the bloodstream. By interrupting this reabsorption, dapagliflozin promotes the removal of excess glucose through urine, thereby lowering circulating glucose levels. This process is independent of insulin signaling, which explains the drug’s efficacy even in patients with impaired insulin secretion.

Dosage Guidelines

Oxra is typically prescribed as one 5 mg tablet taken once daily, regardless of meals. The recommended starting dose for most adults with type 2 diabetes is 5 mg daily, and the dose may be titrated to 10 mg based on glycemic response and tolerability, as determined by the prescribing clinician. Patients with renal impairment (estimated glomerular filtration rate [eGFR] below 60 mL/min/1.73 m²) may require dose adjustment, and dapagliflozin is not recommended for use in patients with severe renal dysfunction (eGFR < 30 mL/min/1.73 m²). It is essential that patients follow the dosing instructions provided by their healthcare provider and undergo periodic renal function monitoring.

Side Effects

Like all medications, Oxra can be associated with adverse effects. The most commonly reported side effects include genital mycotic infections, urinary tract infections, and polyuria. Rare but serious adverse events may involve ketoacidosis, severe renal impairment, and volume depletion. Patients should be advised to maintain adequate hydration and to report any persistent urinary symptoms or signs of infection. It is also important to monitor for hypoglycemia when Oxra is used in combination with insulin or sulfonylureas, as the risk of low blood glucose may increase.

Warnings and Precautions

Before initiating therapy with Oxra, healthcare professionals should assess patients for factors that may increase the risk of complications, such as a history of renal disease, dehydration, or chronic alcohol use. Concomitant use of other medications that affect renal function or glucose regulation should be reviewed carefully. Patients should be instructed to discontinue the medication temporarily during episodes of acute illness, surgery, or procedures that may impact renal perfusion. Additionally, Oxra is contraindicated in patients with a known hypersensitivity to dapagliflozin or any of the inactive ingredients, and it should not be used in patients with type 1 diabetes or in pediatric populations unless specifically indicated by regulatory authorities.

Frequently Asked Questions

1. What is the typical starting dose of Oxra? The usual starting dose is one 5 mg tablet taken once daily. Dose escalation to 10 mg may be considered based on clinical response.

2. Can Oxra be used in patients with kidney disease? Oxra should be used with caution in patients with reduced renal function. It is not recommended for individuals with an eGFR below 30 mL/min/1.73 m².

3. Is Oxra safe during pregnancy or breastfeeding? The safety of Oxra during pregnancy and lactation has not been established. Women of childbearing potential should use effective contraception while taking the medication, and healthcare providers should discuss alternative treatments.

4. How does Oxra affect cardiovascular health? Clinical trials have shown that dapagliflozin can reduce the risk of hospitalization for heart failure and may provide cardiovascular benefits in patients with type 2 diabetes who have existing heart disease.

5. Where can I find more detailed prescribing information? The full prescribing information, including FDA‑approved labeling, is available on the manufacturer’s website and through authoritative drug databases such as Drugs.com and MedlinePlus.

For additional scientific details, you may refer to resources from the U.S. Food and Drug Administration, the National Institutes of Health, and the MedlinePlus database.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)